Volume 7.11 Mar 26

Mammary Cell News 7.11 March 26, 2015
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
Blocking Cellular Quality Control Mechanism Gives Cancer Chemotherapy a Boost
Scientists found a way to make chemotherapy more effective, by stopping a cellular quality-control mechanism. The mechanism is known as NMD (nonsense-mediated mRNA decay), and they found that exposing breast cancer cells to a molecule that inhibits NMD prior to treatment with doxorubicin, a drug used to treat leukemia, breast, bone, lung and other cancers, hastens cell death. [Press release from the University of Rochester discussing online publication in Nature Communications] Press Release | Abstract
See Who's Published: Leading Breast Cancer Researchers Use MammoCult™
PUBLICATIONS (Ranked by impact factor of the journal)

Inhibition of Breast Cancer Invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 Pathway Targeting Actin Nucleators, mDia Genes
Researchers report that TIS21/BTG2/Pc3 downregulated diaphanous-related formin expression via reducing NADPH oxidase 4 (Nox4)-derived reactive oxygen species generation by Akt1 activation and subsequently impaired invasion activity of the highly invasive breast cancer cells. [Oncogene] Abstract

β2-AR Signaling Controls Trastuzumab Resistance-Dependent Pathway
Investigators showed that the expression of β2-adrenergic receptor (β2-AR), which mediates most catecholamine-induced effects, negatively correlated with trastuzumab response in the patients with Her2-overexpressing breast cancer. Catecholamines potently antagonized the anti-proliferative effects of trastuzumab both in vitro and in vivo. [Oncogene] Abstract

PI3K/mTOR Mediate Mitogen-Dependent HDAC1 Phosphorylation in Breast Cancer: A Novel Regulation of Estrogen Receptor Expression
Researchers showed how mitogens, activating the PI3K/mTOR pathway, trigger the phosphorylation of histone deacetylase 1 (HDAC1) in breast cancer cells, which is completely dependent on the activity of the p70 S6 kinase. [J Mol Cell Biol] Abstract

Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells
Scientists took a synthetic lethal approach to determine whether the loss of E-cadherin creates druggable vulnerabilities. They conducted a 4,057 known drug screen and time course studies on the CDH1 isogenic MCF10A cell lines and identified additional drug classes with linkages to G-protein coupled receptor (GPCR) signaling and cytoskeletal function that showed evidence of E-cadherin synthetic lethality. [Mol Cancer Ther] Abstract | Press Release

Nifuroxazide Induces Apoptosis and Impairs Pulmonary Metastasis in Breast Cancer Model
The potency of nifuroxazide on breast cancer was assessed in vitro and in vivo. Investigators found that nifuroxazide decreased the viability of three breast cancer cell lines and induced apoptosis of cancer cells in a dose-dependent manner. [Cell Death Dis] Full Article

p53-Dependent Expression of CXCR5 Chemokine Receptor in MCF-7 Breast Cancer Cells
Researchers demonstrated an inverse correlation between expression levels of p53 tumor suppressor and CXCR5 chemokine receptor in MCF-7 human breast cancer cell line. Functional activity of CXCR5 in p53-knockdown MCF-7 cells was increased as shown by activation of target gene expression and chemotaxis in response to B-lymphocyte chemoattractant CXCL13. [Sci Rep] Full Article

Selective Targeting of FAK-Pyk2 Axis by Alpha-Naphthoflavone Abrogates Doxorubicin Resistance in Breast Cancer Cells
Researchers examined the therapeutic efficacy of alpha-naphthoflavone in doxorubicin-resistant MCF-7 (MCF-7/Dox) breast cancer cells and investigated its underlying molecular mechanisms of action. MCF-7/Dox cells expressed constitutively active forms of the tyrosine kinases: focal adhesion kinase (FAK-Y397) and protein tyrosine kinase 2 beta (Pyk2- Y579/580) compared with parental MCF-7 cells. [Cancer Lett] Abstract

Runx1 Is Associated with Breast Cancer Progression in MMTV-PyMT Transgenic Mice and Its Depletion In Vitro Inhibits Migration and Invasion
The authors addressed whether Runx1 has a specific pathological role during breast cancer progression and show that Runx1 has an oncogenic function. They observed elevated Runx1 expression in a subset of human breast cancers. [J Cell Physiol] Abstract

ABL Tyrosine Kinase Inhibition Variable Effects on the Invasive Properties of Different Triple Negative Breast Cancer Cell Lines
Scientists investigated nilotinib effect on the invasive and migratory properties of different triple negative (TN) breast cancer cell lines. Nilotinib decreased both matrix degradation and invasion in the TN breast cancer cell lines MDA-MB 231 and MDA-MB 468. [PLoS One] Full Article


Cisplatin plus Gemcitabine versus Paclitaxel plus Gemcitabine as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (CBCSG006): A Randomized, Open-Label, Multicenter, Phase III Trial
Investigators assessed whether a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. [Lancet Oncol] Abstract

Lapatinib or Trastuzumab plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC
The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 -positive metastatic breast cancer was investigated by scientists. [J Clin Oncol] Full Article | Editorial

Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
Taconic Biosciences and Cellaria Biosciences Agree to Scientific Collaboration to Facilitate Xenograft Use in Oncology Research
Taconic Biosciences and Cellaria Biosciences announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts. [Taconic Biosciences, Inc.] Press Release

“How Does Breast Cancer Develop?” Pilot Grants Awarded to Multidisciplinary Teams Using the Intraductal Approach to Advance Breast Cancer Prevention
Dr. Susan Love Research Foundation awarded four innovative pilot grants to research projects that will explore using next generation technology to investigate the human breast and how it develops cancer. [Dr. Susan Love Research Foundation] Press Release

ACGT Surpasses $25 Million Funding Milestone with Two New Grants
Alliance for Cancer Gene Therapy (ACGT) has achieved a major milestone, surpassing $25 million donated to innovative and breakthrough cancer research. [Alliance for Cancer Gene Therapy (Vocus PRW Holdings, LLC.)] Press Release

Accellta Grants Exclusive Rights for Micro-Carrier Free Stem Cells Suspension Culture to STEMCELL Technologies
The stem cell company Accellta announced that it has granted exclusive worldwide rights to STEMCELL Technologies Inc. for manufacturing and distribution of medium for culturing pluripotent stem cells in suspension under feeder-free, non-adherent conditions. [Accellta Ltd.] Press Release

Ellis Receives ASCO Award for Contributions to Breast Cancer Genomics Research, Mentorship
Dr. Matthew Ellis, director of the Lester and Sue Smith Breast Center at Baylor College of Medicine, has been named recipient of the 2015 American Society of Clinical Oncology (ASCO)’s Gianni Bonadonna Breast Cancer Award and Lecture, an honor given annually to an oncologist for outstanding contributions to basic or translational research in breast cancer and exceptional mentoring abilities. [Baylor College of Medicine] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Gordon Research Conference – Hormone-Dependent Cancers
August 16-21, 2015
Newry, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Research Technician – Breast Cancer Research (King’s College London)

NEW Postdoctoral Position – Triple Negative Breast Cancer (King’s College London)

NEW Postdoctoral Fellow – Breast Cancer & Stem Cell Biology (University of Cincinnati)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Senior Scientific Operations Manager – Breast Cancer Research (Institute of Cancer Research)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati College of Medicine)

Postdoctoral Fellow – Cancer/Breast Cancer Genomic Instability and Cell Biology (University of Queensland)

Research Associate – Division of Cancer Studies (King’s College London)

Clinician Scientist (National University of Singapore)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us